{"id":"NCT01628926","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients","officialTitle":"A Double-Blind, 3-Arm, Parallel Group, Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2012-06-27","resultsPosted":"2014-05-23","lastUpdate":"2014-05-23"},"enrollment":420,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"SPM 962","otherNames":[]},{"type":"DRUG","name":"Ropinirole","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SPM 962","type":"EXPERIMENTAL"},{"label":"Ropinirole","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"* To demonstrate the non-inferiority of SPM 962 to ropinirole in terms of efficacy in order to confirm clinical value of SPM 962.\n* To demonstrate the superiority of SPM 962 to placebo in terms of efficacy.\n* To investigate the tolerability and safety of SPM 962 up to 36.0 mg/day.","primaryOutcome":{"measure":"Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score","timeFrame":"baseline, 16 weeks after dosing","effectByArm":[{"arm":"SPM 962","deltaMin":-10.9,"sd":8.1},{"arm":"Ropinirole","deltaMin":-9.5,"sd":8.7},{"arm":"Placebo","deltaMin":-4.5,"sd":9.7}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":21},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":168},"commonTop":["Application Site Reaction","Nasopharyngitis","Nausea","Dyskinesia","Hallucination Visual"]}}